Organic Active Ingredients TRIZ Cases

Topical methylene blue and rapamycin clear progerin aggregates via autophagy, restoring nuclear envelope integrity in premature aging cells.

Formula I compounds block IDH mutant alpha hydroxyl neoactivity, reducing 2HG accumulation in cancer cells.

Novel phosphonate compounds inhibit resistant influenza neuraminidases.

Glucocorticoid receptor antagonists increase pituitary ACTH secretion, resolving invasive catheterization and CRH shortages in Cushing's syndrome diagnosis.

An LM-1 antibody binds the NONO/nmt55 antigen on cancer cells to induce apoptosis and reduce cellular proliferation.

Novel coelenterazine derivatives with specific bicyclic structures exhibit high luminescence brightness and enzyme specificity.

Anti-OX40L antibodies reduce cytokine secretion and leukocyte proliferation by blocking the OX40/OX40L interaction, addressing inadequate GvHD management.

Granular estetrol formulation with sugar alcohols dissolves rapidly in saliva for direct mucosal absorption.

A pharmaceutical composition containing diindolylmethane and gingerol derivatives enhances insulin release through targeted molecular modulation.

Modified AAV capsid proteins enhance heparan sulfate binding to improve retinal cell transduction efficiency.

Sequential additive addition to hypromellose dispersion prevents plating deterioration while improving bioavailability.

Polyrotaxane carriers resolve rapid clearance and toxicity trade-offs by sustaining cholesterol removal in Niemann-Pick type C disease.

Heating the active ingredient above its melting point and solidifying it within polyvinyl alcohol eliminates binder instability.

Novel lurasidone dihydrochloride hydrate salt overcomes poor bioavailability of the monohydrochloride form by enhancing water solubility and stability.

Selective 5-HT2A antagonism by substituted heterocycle fused gamma-carboline reduces side effects from high dopamine D2 pathway occupancy.

Edonentan crystalline form 4 reduces intraocular pressure and improves retinal perfusion while addressing inadequate treatment effectiveness.

Segmented peptide epitopes target tumor-associated antigens with high affinity, reducing off-target side effects in immunotherapy.

Single-stranded DNA aptamers bind activated NF-kB/RelA to quantify protein levels, resolving low sensitivity in conventional detection methods.

Clay-anesthetic composites protect ester bonds from hydrolysis while creating an occlusive effect that extends pain control duration.

SK1 inhibitors and S1P receptor agonists target sphingosine pathways to induce cancer cell apoptosis while sparing normal tissue.

A meloxicam piperazine derivative dissolves in mixed solvents to enable intravenous injection.

Formula I compounds inhibit VMAT2 to treat neurological disorders while minimizing sedation and Parkinsonism side effects.

A quinazoline derivative overcomes drug resistance by irreversibly inhibiting EGFR tyrosine kinase through covalent bonding at the ATP binding site.

A granulated pharmaceutical substance containing an alkaline agent and surfactant enhances drug solubility through localized chemical environment control.

Replacing subjective behavioral assessments with molecular genetic testing resolves the diagnostic accuracy versus method complexity contradiction.

Streptavidin-desthiobiotin interactions enable sustained drug release over months, reducing injection frequency and ocular complications.

Novel amine prodrugs attach specific appendage moieties to riluzole molecules, creating hybrid structures with enhanced physiochemical properties.

Synthetic human milk oligosaccharides increase Bifidobacterium adolescentis abundance in the gastrointestinal tract.

Segmented pyrimidine structures target specific JNK isoforms, resolving limited treatment effectiveness in liver fibrosis.

Heterocyclic compounds inhibit monoacylglycerol lipase to raise 2-AG levels and reduce AA-derived eicosanoids for treating neuroinflammation.

Administering an agent that blocks IL-11 receptor binding removes pro-fibrotic signaling to alleviate fibrosis.

A pyrimidylpyrazole compound inhibits melanin production in cosmetic preparations.

Pyridine-2-carboxamide derivatives activate glucokinase to regulate blood sugar levels and improve glucose metabolism in type 2 diabetes treatment.

Injectable naltrexone sustained release formulation using biocompatible solvents and 3-acyl derivatives to maintain effective plasma concentrations.

Crystalline acalabrutinib maleate monohydrate maintains high dissolution rates and stability across varying stomach pH conditions.

Adiporon activates adiponectin receptors to improve bone density while reducing inflammation and oxidative stress in diabetic osteoporosis.

Cyclic polypeptides inhibit PCSK9 binding to LDLR, preventing receptor degradation and reducing hypercholesterolemia risk.

Stabilizers like L-methionine shield sarcophagine-copper complexes from radiolysis, maintaining radiochemical purity and bioavailability.

Isolated 3-(3,4-dihydroxy phenyl) propanoic acid derivatives selectively target Src kinase to treat chronic myeloid leukemia and breast cancer.

Targeting CLDN6 on cancer stem cells eliminates chemoresistant populations, preventing tumor recurrence and metastasis.

Liquid-to-gel phase transition extends drug retention time and bioavailability while avoiding blurred vision associated with traditional ointments.

Amide compounds restore mutant CFTR protein folding to improve chloride transport, addressing ΔF508 mutation defects.

Aptamer pairs with anti-aptamers enable sensitive detection of small molecules lacking multiple epitopes.

Pyrroloy[1,2-a]imidazoledione compounds protect nerve cells from chemotherapy damage.

S1PC activates autophagy to clear tau proteins while minimizing side effects in neurodegenerative disease treatment.